Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.

Copinschi G, Leproult R, Van Onderbergen A, Caufriez A, Cole KY, Schilling LM, Mendel CM, De Lepeleire I, Bolognese JA, Van Cauter E

Neuroendocrinology1 Oct 1997Cited by 46 (Europe PMC)

PMID9349662DOI10.1159/000127249PepBankPUB-09349662

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In young adults, high-dose MK‑677 increased stage IV sleep duration by approximately 50% compared with placebo.
In plain wordsIn young adults, high-dose MK‑677 increased deep sleep duration compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseStage IV sleep duration
Study
n = 8
Comparator
Placebo
Outcome group
Sleep · Sleep
Studied dose
25 mg · oral · 7 daysAs given in this study (human).
Measurements
Stage IV sleep duration increase vs placebo
≈ 50%
young adults, high-dose MK-677
p value for Stage IV sleep duration
< 0.05 p
young adults, high-dose MK-677 vs placebo
Source sentences
Summary
In young subjects, high-dose MK-677 treatment resulted in an approximately 50% increase in the duration of stage IV and in a more than 20% increase in REM sleep as compared to placebo (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Eight young subjects (18-30 years) followed a double-blind, placebo-controlled, three-period crossover design.
Summary · context
Each subject participated in three 7-day treatment periods (with bedtime drug administration), presented in random (Latin square) order, and separated by at least 14 days.
Summary · context
Doses were 5 and 25 mg MK-677 and matching placebo.
Report a problemFND-0934966201
02HumanRandomized controlled trialEfficacy outcome
In young adults, high-dose MK‑677 increased REM sleep by more than 20% compared with placebo.
In plain wordsIn young adults, high-dose MK‑677 increased REM sleep compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseREM sleep duration in young adults
Study
n = 8
Comparator
Placebo
Outcome group
Sleep · Sleep
Studied dose
25 mg · oral · 7 daysAs given in this study (human).
Measurements
REM sleep increase vs placebo
> 20%
young adults, high-dose MK-677
p value for REM sleep duration in young adults
< 0.05 p
young adults, high-dose MK-677 vs placebo
Source sentences
Summary
In young subjects, high-dose MK-677 treatment resulted in an approximately 50% increase in the duration of stage IV and in a more than 20% increase in REM sleep as compared to placebo (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Eight young subjects (18-30 years) followed a double-blind, placebo-controlled, three-period crossover design.
Summary · context
Each subject participated in three 7-day treatment periods (with bedtime drug administration), presented in random (Latin square) order, and separated by at least 14 days.
Summary · context
Doses were 5 and 25 mg MK-677 and matching placebo.
Report a problemFND-0934966202
03HumanRandomized controlled trialEfficacy outcome
In young adults, deviations from normal sleep decreased from 42% with placebo to 8% with high-dose MK‑677.
In plain wordsIn young adults, high-dose MK‑677 reduced deviations from normal sleep compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseDeviations from normal sleep in young adults
Study
n = 8
Comparator
Placebo
Outcome group
Sleep · Sleep
Studied dose
25 mg · oral · 7 daysAs given in this study (human).
Measurements
Frequency of deviations from normal sleep
42%
young adults, placebo
Frequency of deviations from normal sleep
8%
young adults, high-dose MK-677
p value for Deviations from normal sleep in young adults
< 0.03 p
young adults, high-dose MK-677 vs placebo
Source sentences
Summary
The frequency of deviations from normal sleep decreased from 42% under placebo to 8% under high-dose MK-677 (p < 0.03).
3 context sentences(design, population, supporting numbers)
Summary · context
Eight young subjects (18-30 years) followed a double-blind, placebo-controlled, three-period crossover design.
Summary · context
Each subject participated in three 7-day treatment periods (with bedtime drug administration), presented in random (Latin square) order, and separated by at least 14 days.
Summary · context
Doses were 5 and 25 mg MK-677 and matching placebo.
Report a problemFND-0934966203
04HumanNon-randomized trialEfficacy outcome
In older adults, MK‑677 was associated with a nearly 50% increase in REM sleep.
In plain wordsIn older adults, MK‑677 was linked to increased REM sleep.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseREM sleep duration in older adults
Study
n = 6
Outcome group
Sleep · Sleep
Studied dose
Dose not stated · oral · 14 daysAs given in this study (human).
Measurements
REM sleep increase
≈ 50%
older adults, MK-677
p value for REM sleep duration in older adults
< 0.05 p
older adults, MK-677 treatment, comparator not stated
Source sentences
Summary
In older adults, treatment with MK-677 was associated with a nearly 50% increase in REM sleep (p < 0.05) and a decrease in REM latency (p < 0.02).
3 context sentences(design, population, supporting numbers)
Summary · context
Six older subjects, ages 65-71 years, each participated in two 14-day treatment periods (with bedtime drug administration) separated by a 14-day washout.
Summary · context
Doses were 2 and 25 mg MK-677 during the first and second periods, respectively.
Summary · context
Baseline sleep and hormonal data were obtained on the 2 days preceding the beginning of the first 14-day treatment period.
Report a problemFND-0934966204
05HumanNon-randomized trialEfficacy outcome
In older adults, MK‑677 was associated with decreased REM latency.
In plain wordsIn older adults, MK‑677 was linked to a shorter time before REM sleep.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseREM latency in older adults
Study
n = 6
Outcome group
Sleep · Sleep
Studied dose
Dose not stated · oral · 14 daysAs given in this study (human).
Measurements
p value for REM latency in older adults
< 0.02 p
older adults, MK-677 treatment, comparator not stated
Source sentences
Summary
In older adults, treatment with MK-677 was associated with a nearly 50% increase in REM sleep (p < 0.05) and a decrease in REM latency (p < 0.02).
3 context sentences(design, population, supporting numbers)
Summary · context
Six older subjects, ages 65-71 years, each participated in two 14-day treatment periods (with bedtime drug administration) separated by a 14-day washout.
Summary · context
Doses were 2 and 25 mg MK-677 during the first and second periods, respectively.
Summary · context
Baseline sleep and hormonal data were obtained on the 2 days preceding the beginning of the first 14-day treatment period.
Report a problemFND-0934966205
06HumanNon-randomized trialEfficacy outcome
In older adults, deviations from normal sleep decreased during MK‑677 treatment.
In plain wordsIn older adults, deviations from normal sleep decreased during MK‑677 treatment.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseDeviations from normal sleep in older adults
Study
n = 6
Outcome group
Sleep · Sleep
Studied dose
Dose not stated · oral · 14 daysAs given in this study (human).
Measurements
p value for Deviations from normal sleep in older adults
< 0.02 p
older adults, MK-677 treatment, comparator not stated
Source sentences
Summary
The frequency of deviations from normal sleep also decreased (p < 0.02).
4 context sentences(design, population, supporting numbers)
Summary · context
In older adults, treatment with MK-677 was associated with a nearly 50% increase in REM sleep (p < 0.05) and a decrease in REM latency (p < 0.02).
Summary · context
Six older subjects, ages 65-71 years, each participated in two 14-day treatment periods (with bedtime drug administration) separated by a 14-day washout.
Summary · context
Doses were 2 and 25 mg MK-677 during the first and second periods, respectively.
Summary · context
Baseline sleep and hormonal data were obtained on the 2 days preceding the beginning of the first 14-day treatment period.
Report a problemFND-0934966206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.